Premium
The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria
Author(s) -
Hombhanje F.W.,
Hwaihwanje I.,
Tsukahara T.,
Saruwatari J.,
Nakagawa M.,
Osawa H.,
Paniu M.M.,
Takahashi N.,
Lum J.K.,
Aumora B.,
Masta A.,
Sapuri M.,
Kobayakawa T.,
Kaneko A.,
Ishizaki T.
Publication year - 2005
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2004.02257.x
Subject(s) - amodiaquine , cyp2c8 , malaria , disposition , plasmodium falciparum , regimen , medicine , pharmacokinetics , pharmacology , oral administration , traditional medicine , immunology , cyp3a4 , psychology , metabolism , social psychology , cytochrome p450
Aims We assessed the disposition of oral amodiaquine (AQ) and CYP2C8 polymorphism in 20 children with falciparum malaria. Methods AQ and DEAQ concentrations were determined with SPE‐HPLC method. CYP2C8 genotypes were assessed by PCR‐RFLP method. Results AQ was not detectable beyond day 3 postdose. C max for DEAQ was reached in 3.0 days. The mean values for t 1/2 , MRT, and AUC total were 10.1 days, 15.5 days and 4512.6 µg l −1 day, respectively. All the children were CYP2C8* homozygous. Conclusion Our data are consistent with those previously reported, and the AQ regimen seems pharmacokinetically adequate in the absence of CYP2C8 polymorphism.